{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:00:13Z","timestamp":1793289613954,"version":"4.5.0"},"reference-count":143,"publisher":"National Institute for Health and Care Research","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["NIHR135822"],"award-info":[{"award-number":["NIHR135822"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalslibrary.nihr.ac.uk"],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"<jats:sec id=\"abs1-1\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Breast cancer is the most commonly diagnosed cancer in women in England. Breast cancer and chemotherapy treatment can impact upon patients\u2019 quality of life and survival. Tumour profiling tests can help to identify whether patients will benefit from chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-2\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the effectiveness and cost-effectiveness of four tumour profiling tests (Oncotype DX, Prosigna, EPclin and MammaPrint), compared with current decision-making (no testing), to guide use of adjuvant chemotherapy in people with hormone-receptor positive, human epidermal growth factor receptor 2 negative, early-stage breast cancer with one to three positive lymph nodes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-3\">\n                    <jats:title>Methods and data sources<\/jats:title>\n                    <jats:p>A systematic review identified studies via a literature search in April 2023 and from our previous review. The economic analysis included a review of existing models and development of an independent model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-4\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fifty-five articles were included, 42 for prognostic and predictive ability and 13 for impact on chemotherapy decisions. All four tests showed prognostic ability for determining risk of relapse. The RxPONDER randomised controlled trial of Oncotype DX indicated no chemotherapy benefit in post-menopausal lymph node-positive patients with a recurrence score of 0\u201325, but a statistically significant benefit in pre-menopausal patients with a recurrence score of 0\u201325. An older randomised controlled trial reanalysis (Southwest Oncology Group-8814) indicated lower relative chemotherapy benefit with lower recurrence score, with statistically significant interactions between recurrence score and chemotherapy benefit in some but not all analyses. There was no clear evidence of prediction of relative chemotherapy benefit for Prosigna, EPclin or MammaPrint. Decision impact studies in lymph node-positive populations in the United Kingdom and Europe were only available for Oncotype DX, and they reported a reduction of 12\u201375% in chemotherapy recommendations following testing.<\/jats:p>\n                    <jats:p>Based on the list prices of the tests and downstream treatments, the independent model suggests the following:<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-5\">\n                    <jats:title>Oncotype DX<\/jats:title>\n                    <jats:p>This test dominates current decision-making in post-menopausal lymph node-positive women, provided an assumption of predictive benefit holds, but the test is dominated if this assumption does not hold. The test is dominated by current decision-making in pre-menopausal lymph node-positive women.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-6\">\n                    <jats:title>Prosigna<\/jats:title>\n                    <jats:p>The probabilistic incremental cost-effectiveness ratio for Prosigna versus current decision-making in post-menopausal lymph node-positive women is \u00a339,357 per quality-adjusted life-year gained.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-7\">\n                    <jats:title>EPclin<\/jats:title>\n                    <jats:p>The probabilistic incremental cost-effectiveness ratio for EPclin versus current decision-making in post-menopausal lymph node-positive women is \u00a34113 per quality-adjusted life-year gained.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-8\">\n                    <jats:title>MammaPrint<\/jats:title>\n                    <jats:p>Within clinical high-risk pre-\/post-menopausal lymph node-positive women, MammaPrint is dominated by current decision-making.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-9\">\n                    <jats:title>Limitations<\/jats:title>\n                    <jats:p>There are limited data on the prediction of chemotherapy benefit; evidence for Oncotype DX may support a predictive benefit, but this is uncertain. Decision impact studies in a lymph node-positive population were available only for Oncotype DX. The economic model relies on an assumption of predictive benefit for Oncotype DX, and broader assumptions around the way that Prosigna, MammaPrint and EPclin test results would affect chemotherapy decisions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-10\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>All four tests provide prognostic information on the risk of relapse. The evidence on prediction of relative chemotherapy benefit is weaker and mostly limited to Oncotype DX. The economic analyses indicate that Oncotype DX and EPclin may have favourable cost-effectiveness profiles in post-menopausal lymph node-positive subgroups, although this is uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-11\">\n                    <jats:title>Study registration<\/jats:title>\n                    <jats:p>This study is registered as PROSPERO CRD42023425638.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-12\">\n                    <jats:title>Funding<\/jats:title>\n                    <jats:p>\n                      This award was funded by the National Institute for Health and Care Research (NIHR) Evidence Synthesis Programme (NIHR award ref: NIHR135822) and is published in full in\n                      <jats:italic>Health Technology Assessment<\/jats:italic>\n                      ; Vol. 29, No. 49. See the NIHR Funding and Awards website for further award information.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3310\/kgfd4040","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T09:14:31Z","timestamp":1739524471000},"page":"1-158","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Tumour profiling tests to guide adjuvant chemotherapy decisions in lymph node-positive early breast cancer: a systematic review and economic evaluation"],"prefix":"10.3310","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6612-2332","authenticated-orcid":true,"given":"Paul","family":"Tappenden","sequence":"first","affiliation":[{"name":"Sheffield Centre for Health and Related Research (SCHARR), School of Medicine and Population Health, University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7702-8103","authenticated-orcid":true,"given":"Katy","family":"Cooper","sequence":"additional","affiliation":[{"name":"Sheffield Centre for Health and Related Research (SCHARR), School of Medicine and Population Health, University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3326-9842","authenticated-orcid":true,"given":"Jean","family":"Hamilton","sequence":"additional","affiliation":[{"name":"Sheffield Centre for Health and Related Research (SCHARR), School of Medicine and Population Health, University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5414-9383","authenticated-orcid":true,"given":"Gamze","family":"Nalbant","sequence":"additional","affiliation":[{"name":"Sheffield Centre for Health and Related Research (SCHARR), School of Medicine and Population Health, University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2397-402X","authenticated-orcid":true,"given":"Munira","family":"Essat","sequence":"additional","affiliation":[{"name":"Sheffield Centre for Health and Related Research (SCHARR), School of Medicine and Population Health, University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6458-1663","authenticated-orcid":true,"given":"Annabel","family":"Rayner","sequence":"additional","affiliation":[{"name":"Sheffield Centre for Health and Related Research (SCHARR), School of Medicine and Population Health, University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4536-4794","authenticated-orcid":true,"given":"Ruth","family":"Wong","sequence":"additional","affiliation":[{"name":"Sheffield Centre for Health and Related Research (SCHARR), School of Medicine and Population Health, University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1063-1717","authenticated-orcid":true,"given":"Nicol\u00f2 Matteo Luca","family":"Battisti","sequence":"additional","affiliation":[{"name":"Department of Medicine, Breast Unit, The Royal Marsden NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4046-5940","authenticated-orcid":true,"given":"Lynda","family":"Wyld","sequence":"additional","affiliation":[{"name":"Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5103-1673","authenticated-orcid":true,"given":"Uzma","family":"Asghar","sequence":"additional","affiliation":[{"name":"Department of Medicine, Breast Unit, The Royal Marsden NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2025,10]]},"reference":[{"key":"key2025101120015500_ref1-bib1","volume-title":"Breast Cancer Incidence (Invasive) Statistics \u2013 Breast Cancer Incidence by Gender and UK Country","author":"Cancer Research UK","year":"2023"},{"key":"key2025101120015500_ref2-bib2","doi-asserted-by":"crossref","DOI":"10.36255\/exon-publications-breast-cancer","volume-title":"Breast Cancer","author":"Mayrovitz","year":"2022"},{"key":"key2025101120015500_ref4-bib4","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1046\/j.1445-1433.2001.02266.x","article-title":"Frequency and predictors of axillary lymph node metastases in invasive breast cancer","volume":"71","author":"Chua","year":"2001","journal-title":"ANZ J Surg"},{"key":"key2025101120015500_ref5-bib5","volume-title":"Cancer Survival in England, Cancers Diagnosed 2016 to 2020, Followed up to 2021","author":"NHS Digital","year":"2023"},{"key":"key2025101120015500_ref6-bib6","volume-title":"Breast Cancer Incidence (Invasive) Statistics \u2013 Breast Cancer Incidence by Age","author":"Cancer Research UK","year":"2023"},{"key":"key2025101120015500_ref7-bib7","volume-title":"Breast Cancer Mortality Statistics \u2013 Breast Cancer Mortality by Age and UK Country","author":"Cancer Research UK","year":"2023"},{"key":"key2025101120015500_ref8-bib8","volume-title":"StatPearls","author":"Rosen","year":"2023"},{"key":"key2025101120015500_ref9-bib9","volume-title":"AJCC Cancer Staging Manual","author":"Amin","year":"2018"},{"key":"key2025101120015500_ref10-bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta23300","article-title":"Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis","volume":"23","author":"Harnan","year":"2019","journal-title":"Health Technol Assess"},{"key":"key2025101120015500_ref12-bib12","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13058-017-0852-3","article-title":"An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation","volume":"19","author":"Candido Dos Reis","year":"2017","journal-title":"Breast Cancer Res"},{"key":"key2025101120015500_ref15-bib15","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/bjc.1982.62","article-title":"A prognostic index in primary breast cancer","volume":"45","author":"Haybittle","year":"1982","journal-title":"Br J Cancer"},{"key":"key2025101120015500_ref16-bib16","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0140-6736(11)61625-5","article-title":"Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials","volume":"379","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2012","journal-title":"Lancet"},{"key":"key2025101120015500_ref18-bib18","first-page":"1","article-title":"A UK prospective multicentre decision impact, decision conflict and economic evaluation of the 21-gene assay in women with node+ve, hormone receptor+ve, HER2-ve breast cancer. Manuscript provided as academic-in-confidence","author":"Holt","year":"2023"},{"key":"key2025101120015500_ref19-bib19","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3109\/0284186X.2010.533190","article-title":"Late effects of breast cancer treatment and potentials for rehabilitation","volume":"50","author":"Ewertz","year":"2011","journal-title":"Acta Oncol"},{"key":"key2025101120015500_ref20-bib20","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1001\/jamaoncol.2017.5524","article-title":"Comparison of the performance of 6 prognostic signatures for estrogen receptor-positive breast cancer: a secondary analysis of a randomized clinical trial","volume":"4","author":"Sestak","year":"2018","journal-title":"JAMA Oncol"},{"key":"key2025101120015500_ref21-bib21","volume-title":"Number Stages of Breast Cancer","author":"Cancer Research UK","year":"2023"},{"key":"key2025101120015500_ref22-bib22","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"key2025101120015500_ref26-bib26","volume-title":"Additional Information Provided to NICE","author":"Veracyte","year":"2023"},{"key":"key2025101120015500_ref27-bib27","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"key2025101120015500_ref28-bib28","doi-asserted-by":"crossref","first-page":"51","DOI":"10.7326\/M18-1376","article-title":"PROBAST: a tool to assess the risk of bias and applicability of prediction model studies","volume":"170","author":"Wolff","year":"2019","journal-title":"Ann Intern Med"},{"key":"key2025101120015500_ref29-bib29","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","article-title":"21-gene assay to inform chemotherapy benefit in node-positive breast cancer","volume":"385","author":"Kalinsky","year":"2021","journal-title":"N Engl J Med"},{"key":"key2025101120015500_ref30-bib30","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S1470-2045(21)00007-3","article-title":"70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age","volume":"22","author":"Piccart","year":"2021","journal-title":"Lancet Oncol"},{"key":"key2025101120015500_ref31-bib31","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1200\/JCO.2015.63.3651","article-title":"Biomarker: predictive or prognostic?","volume":"33","author":"Ballman","year":"2015","journal-title":"J Clin Oncol"},{"key":"key2025101120015500_ref32-bib32","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1470-2045(09)70314-6","article-title":"Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial","volume":"11","author":"Albain","year":"2010","journal-title":"Lancet Oncol"},{"key":"key2025101120015500_ref33-bib33","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s10549-008-0130-2","article-title":"The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1\u20133 positive lymph nodes in an independent validation study","volume":"116","author":"Mook","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"key2025101120015500_ref34-bib34","doi-asserted-by":"crossref","first-page":"TPS599","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS599","article-title":"Optima: optimal personalised treatment of early breast cancer using multi-parameter analysis, an international randomized trial of tumor gene expression test directed chemotherapy treatment in a largely node-positive population","volume":"39","author":"Stein","year":"2021","journal-title":"J Clin Oncol"},{"key":"key2025101120015500_ref35-bib35","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/S0960-9776(19)30108-0","article-title":"The Oncotype DX Breast test to guide management of node-positive oestrogen receptor-positive HER2-negative breast cancer patients: the United Kingdom experience","volume":"44","author":"Battisti","year":"2019","journal-title":"Breast"},{"key":"key2025101120015500_ref36-bib36","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS22-P6-01-11","article-title":"A UK prospective multicentre decision impact, decision conflict and economic evaluation of the use of Oncotype DX to guide chemotherapy in 680 women with hormone receptor positive, HER2 negative breast cancer and 1 to 3 nodes involved","volume":"83","author":"Holt","year":"2023","journal-title":"Cancer Res"},{"key":"key2025101120015500_ref37-bib37","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.ejso.2016.12.010","article-title":"Impact of Oncotype DX breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: real world experience in Greater Manchester, UK","volume":"43","author":"Loncaster","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"key2025101120015500_ref38-bib38","first-page":"e1546","article-title":"The impact of Oncotype DX testing on adjuvant chemotherapy decision making in 1\u20133 node positive breast cancer","volume":"5","author":"Malam","year":"2022","journal-title":"Cancer Rep (Hoboken)"},{"key":"key2025101120015500_ref39-bib39","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/j.ejso.2021.03.124","article-title":"P120. Combined experience of utility of genomic profiling in lymph node-positive breast cancer: reduced prescription of chemotherapy and follow-up","volume":"47","author":"Nanda","year":"2021","journal-title":"Eur J Surg Oncol"},{"key":"key2025101120015500_ref40-bib40","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1038\/s41416-024-02588-9","article-title":"A UK prospective multicentre decision impact, decision conflict and economic evaluation of the 21-gene assay in women with node+ve, hormone receptor+ve, HER2-ve breast cancer","volume":"130","author":"Holt","year":"2024","journal-title":"Br J Cancer"},{"key":"key2025101120015500_ref41-bib41","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41523-021-00246-4","article-title":"PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy","volume":"7","author":"Cognetti","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"key2025101120015500_ref42-bib42","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1634\/theoncologist.2017-0322","article-title":"First prospective multicenter Italian study on the impact of the 21-gene recurrence score in adjuvant clinical decisions for patients with ER positive\/HER2 negative breast cancer","volume":"23","author":"Dieci","year":"2018","journal-title":"Oncologist"},{"key":"key2025101120015500_ref43-bib43","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1634\/theoncologist.2019-0103","article-title":"Impact of 21-gene breast cancer assay on treatment decision for patients with T1\u2013T3, N0\u2013N1, estrogen receptor-positive\/human epidermal growth receptor 2-negative breast cancer: final results of the prospective multicenter ROXANE study","volume":"24","author":"Dieci","year":"2019","journal-title":"Oncologist"},{"key":"key2025101120015500_ref44-bib44","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/j.annonc.2021.03.074","article-title":"60P Real-life use of Oncotype DX Breast Recurrence Score test for the management of patients with node-negative and node-positive breast cancer in the autonomous community of Galicia (Spain)","volume":"32","author":"Fernandez-Perez","year":"2021","journal-title":"Ann Oncol"},{"key":"key2025101120015500_ref45-bib45","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.3390\/cancers15051529","article-title":"Impact of the 21-gene assay in patients with high-clinical risk ER-positive and HER2-negative early breast cancer: results of the KARMA Dx study","volume":"15","author":"Llombart-Cussac","year":"2023","journal-title":"Cancers"},{"key":"key2025101120015500_ref46-bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.breast.2020.04.003","article-title":"Prospective observational study on the impact of the 21-gene assay on treatment decisions and resources optimization in breast cancer patients in Lombardy: the BONDX study","volume":"52","author":"Zambelli","year":"2020","journal-title":"Breast"},{"key":"key2025101120015500_ref47-bib47","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/annonc\/mds512","article-title":"The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use","volume":"24","author":"Eiermann","year":"2013","journal-title":"Ann Oncol"},{"key":"key2025101120015500_ref48-bib48","volume-title":"NICE Request \u2013 TransATAC Data Analysis","author":"Sestak","year":"2017"},{"key":"key2025101120015500_ref49-bib49","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10549-017-4550-8","article-title":"21-gene recurrence score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28\/NRG Oncology","volume":"168","author":"Mamounas","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"key2025101120015500_ref50-bib50","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1186\/s12885-018-4331-8","article-title":"The 21-gene Recurrence Score R assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial)","volume":"18","author":"Penault-Llorca","year":"2018","journal-title":"BMC Cancer"},{"key":"key2025101120015500_ref51-bib51","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS22-GS1-01","article-title":"Race and clinical outcomes in the RxPONDER trial (SWOG S1007)","volume":"83","author":"Abdou","year":"2023","journal-title":"Cancer Res"},{"key":"key2025101120015500_ref52-bib52","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1200\/JCO.21.02019","article-title":"Outcome of patients with an ultralow-risk 70-gene signature in the MINDACT trial","volume":"40","author":"Lopes Cardozo","year":"2022","journal-title":"J Clin Oncol"},{"key":"key2025101120015500_ref53-bib53","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s10549-013-2831-4","article-title":"Long-term impact of the 70-gene signature on breast cancer outcome","volume":"143","author":"Drukker","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"key2025101120015500_ref54-bib54","doi-asserted-by":"crossref","first-page":"v60","DOI":"10.1093\/annonc\/mdx362.045","article-title":"The 70-gene signature in node positive breast cancer: 10-year follow-up of the observational RASTER study","volume":"28","author":"Vliek","year":"2017","journal-title":"Ann Oncol"},{"key":"key2025101120015500_ref55-bib55","doi-asserted-by":"crossref","first-page":"S612","DOI":"10.1016\/j.annonc.2022.07.197","article-title":"MammaPrint 10-year follow up results from a German breast cancer cohort study","volume":"33","author":"Jackisch","year":"2022","journal-title":"Ann Oncol"},{"key":"key2025101120015500_ref56-bib56","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/annonc\/mdt494","article-title":"Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone","volume":"25","author":"Gnant","year":"2014","journal-title":"Ann Oncol"},{"key":"key2025101120015500_ref57-bib57","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1158\/1078-0432.CCR-13-1845","article-title":"The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer","volume":"20","author":"Filipits","year":"2014","journal-title":"Clin Cancer Res"},{"key":"key2025101120015500_ref58-bib58","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1200\/JCO.2017.74.6586","article-title":"PAM50 risk of recurrence score predicts 10-year distant recurrence in a comprehensive Danish cohort of postmenopausal women allocated to 5 years of endocrine therapy for hormone receptor-positive early breast cancer","volume":"36","author":"Laenkholm","year":"2018","journal-title":"J Clin Oncol"},{"key":"key2025101120015500_ref59-bib59","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10549-016-3725-z","article-title":"Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM\/9906 sub-study","volume":"156","author":"Martin","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"key2025101120015500_ref60-bib60","doi-asserted-by":"crossref","first-page":"R38","DOI":"10.1186\/bcr3642","article-title":"Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+\/HER2- breast cancer patients: results from the GEICAM 9906 trial","volume":"16","author":"Martin","year":"2014","journal-title":"Breast Cancer Res"},{"key":"key2025101120015500_ref61-bib61","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s10549-019-05446-y","article-title":"Research-based PAM50 signature and long-term breast cancer survival","volume":"179","author":"Pu","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"key2025101120015500_ref62-bib62","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41523-022-00423-z","article-title":"PAM50 subtyping and ROR score add long-term prognostic information in premenopausal breast cancer patients","volume":"8","author":"Lundgren","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"key2025101120015500_ref63-bib63","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1158\/1078-0432.CCR-19-0376","article-title":"Prediction of distant recurrence using EndoPredict among women with ER+, HER2- node-positive and node-negative breast cancer treated with endocrine therapy only","volume":"25","author":"Filipits","year":"2019","journal-title":"Clin Cancer Res"},{"key":"key2025101120015500_ref64-bib64","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1158\/1078-0432.CCR-20-0260","article-title":"Prognostic Value of EndoPredict in women with hormone receptor-positive, HER2-negative Invasive lobular breast cancer","volume":"26","author":"Sestak","year":"2020","journal-title":"Clin Cancer Re"},{"key":"key2025101120015500_ref65-bib65","doi-asserted-by":"crossref","first-page":"4435","DOI":"10.1158\/1078-0432.CCR-22-0619","article-title":"Clinical validation of EndoPredict in pre-menopausal women with ER-positive, HER2-negative primary breast cancer","volume":"28","author":"Constantinidou","year":"2022","journal-title":"Clin Cancer Res"},{"key":"key2025101120015500_ref66-bib66","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41523-017-0033-7","article-title":"Clinical outcomes in ER+ HER2-node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry","volume":"3","author":"Stemmer","year":"2017","journal-title":"NPJ Breast Cancer"},{"key":"key2025101120015500_ref67-bib67","doi-asserted-by":"crossref","first-page":"16017","DOI":"10.1038\/npjbcancer.2016.17","article-title":"Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study","volume":"2","author":"Petkov","year":"2016","journal-title":"NPJ Breast Cancer"},{"key":"key2025101120015500_ref68-bib68","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10549-017-4162-3","article-title":"Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database","volume":"163","author":"Roberts","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"key2025101120015500_ref69-bib69","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1200\/JCO.2017.76.8861","article-title":"Molecular characterization and mortality from breast cancer in men","volume":"36","author":"Massarweh","year":"2018","journal-title":"J Clin Oncol"},{"key":"key2025101120015500_ref70-bib70","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1002\/cncr.32956","article-title":"Propensity score analysis of the prognostic value of genomic assays for breast cancer in diverse populations using the National Cancer Data Base","volume":"126","author":"Ibraheem","year":"2020","journal-title":"Cancer"},{"key":"key2025101120015500_ref71-bib71","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/cncr.31818","article-title":"Community clinical practice patterns and mortality in patients with intermediate oncotype DX recurrence scores: who benefits from chemotherapy?","volume":"125","author":"Ibraheem","year":"2019","journal-title":"Cancer"},{"key":"key2025101120015500_ref72-bib72","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1245\/s10434-022-12699-3","article-title":"Survival benefit of chemotherapy according to 21-gene recurrence score in young women with breast cancer","volume":"30","author":"Nash","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"key2025101120015500_ref73-bib73","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1002\/cncr.34127","article-title":"Adjuvant chemotherapy in patients with invasive lobular carcinoma and use of the 21-gene recurrence score: a National Cancer Database analysis","volume":"128","author":"Weiser","year":"2022","journal-title":"Cancer"},{"key":"key2025101120015500_ref74-bib74","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s10549-020-05971-1","article-title":"The 21-gene recurrence score in node-positive, hormone receptor-positive, HER2-negative breast cancer: a cautionary tale from an NCDB analysis","volume":"185","author":"Weiser","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"key2025101120015500_ref75-bib75","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1200\/JCO.19.01959","article-title":"Prognostic impact of the 21-gene recurrence score assay among young women with node-negative and node-positive ER-positive\/HER2-negative breast cancer","volume":"38","author":"Poorvu","year":"2020","journal-title":"J Clin Oncol"},{"key":"key2025101120015500_ref76-bib76","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s10549-017-4358-6","article-title":"Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial","volume":"165","author":"Nitz","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"key2025101120015500_ref77-bib77","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1159\/000521096","article-title":"Validation of the 21-gene recurrence score assay in patients with hormone receptor-positive, HER2-negative breast cancer and 0 to 3 positive lymph nodes: Risk pattern and outcomes on a community level","volume":"17","author":"Braun","year":"2022","journal-title":"Breast Care (Basel)"},{"key":"key2025101120015500_ref78-bib78","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS21-GS2-07","article-title":"Updated results from a phase 3 randomized clinical trial in participants (pts) with 1\u20133 positive lymph nodes (LN), hormone receptor-positive (HR+) and HER2-negative (HER2\u2212) breast cancer (BC) with recurrence score (RS) < 25 randomized to endocrine therapy (ET)","volume":"82","author":"Kalinsky","year":"2022","journal-title":"Cancer Res"},{"key":"key2025101120015500_ref79-bib79","doi-asserted-by":"crossref","first-page":"S607","DOI":"10.1016\/j.annonc.2022.07.184","article-title":"Clinical outcomes in ER+ breast cancer patients with recurrence score 26\u201330-guided therapy: real-world data","volume":"33","author":"Rotem","year":"2022","journal-title":"Ann Oncol"},{"key":"key2025101120015500_ref80-bib80","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS19-P3-07-01","article-title":"Breast cancer-specific mortality (BCSM) in patients age 50 years or younger with node positive (N+) breast cancer (BC) treated based on the 21-gene assay in clinical practice","volume":"80","author":"Petkov","year":"2020","journal-title":"Cancer Res"},{"key":"key2025101120015500_ref81-bib81","doi-asserted-by":"crossref","first-page":"7739","DOI":"10.1245\/s10434-022-12065-3","article-title":"The 21-gene recurrence score in clinically high-risk lobular and ductal breast cancer: a National Cancer Database study","volume":"29","author":"Abel","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"key2025101120015500_ref82-bib82","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2022.40.16_suppl.540","article-title":"Adjuvant chemotherapy is associated with an overall survival benefit regardless of age in patients with ER+\/HER2-breast cancer with 1\u20133 positive nodes and Oncotype DX recurrence score 20 to 25: a National Cancer Database analysis","volume":"40","author":"Cao","year":"2022","journal-title":"J Clin Oncol"},{"key":"key2025101120015500_ref83-bib83","first-page":"PO.19.00029","article-title":"21-gene recurrence score adds significant value for grade 3 breast cancers: results from a national cohort","volume":"3","author":"Iorgulescu","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"key2025101120015500_ref84-bib84","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS22-P1-01-02","article-title":"The impact of adjuvant chemotherapy on overall survival in hormone and node positive breast cancer patients with an Oncotype Dx score of 25 or less. A NCDB analysis","volume":"83","author":"Kumar","year":"2023","journal-title":"Cancer Res"},{"key":"key2025101120015500_ref86-bib86","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s10549-016-3780-5","article-title":"Impact of genomic testing and patient-reported outcomes on receipt of adjuvant chemotherapy","volume":"156","author":"Evans","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"key2025101120015500_ref87-bib87","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1200\/JCO.2008.20.2119","article-title":"Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection","volume":"28","author":"Lo","year":"2010","journal-title":"J Clin Oncol"},{"key":"key2025101120015500_ref88-bib88","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1186\/1471-2407-13-295","article-title":"Association between genomic recurrence risk and well-being among breast cancer patients","volume":"13","author":"Retel","year":"2013","journal-title":"BMC Cancer"},{"key":"key2025101120015500_ref89-bib89","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/pon.4664","article-title":"Enhancing decision-making about adjuvant chemotherapy in early breast cancer following EndoPredict testing","volume":"27","author":"Fallowfield","year":"2018","journal-title":"Psychooncology"},{"key":"key2025101120015500_ref90-bib90","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1185\/03007995.2015.1037730","article-title":"Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer","volume":"31","author":"Martin","year":"2015","journal-title":"Curr Med Res Opin"},{"key":"key2025101120015500_ref91-bib91","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1185\/03007995.2016.1166102","article-title":"The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer","volume":"32","author":"Wuerstlein","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"key2025101120015500_ref92-bib92","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1080\/13696998.2022.2066399","article-title":"Cost-effectiveness analysis of the Oncotype DX Breast Recurrence Score test in node-positive early breast cancer","volume":"25","author":"Berdunov","year":"2022","journal-title":"J Med Econ"},{"key":"key2025101120015500_ref93-bib93","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.hlpt.2018.12.001","article-title":"The cost-effectiveness of EndoPredict to inform adjuvant chemotherapy decisions in early breast cancer","volume":"8","author":"Hinde","year":"2019","journal-title":"Health Policy Technol"},{"key":"key2025101120015500_ref94-bib94","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3747\/co.26.4769","article-title":"Cost-utility analysis of 21-gene assay for node-positive early breast cancer","volume":"26","author":"Masucci","year":"2019","journal-title":"Curr Oncol"},{"key":"key2025101120015500_ref95-bib95","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.jval.2017.04.021","article-title":"Value of information analysis of multiparameter tests for chemotherapy in early breast cancer: the OPTIMA Prelim trial","volume":"20","author":"Hall","year":"2017","journal-title":"Value Health"},{"key":"key2025101120015500_ref96-bib96","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta20100","article-title":"OPTIMA Prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer","volume":"20","author":"Stein","year":"2016","journal-title":"Health Technol Assess"},{"key":"key2025101120015500_ref97-bib97","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40273-013-0115-9","article-title":"Cost effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in post-menopausal women with early-stage estrogen or progesterone-receptor-positive, axillary lymph-node positive breast cancer","volume":"32","author":"Hannouf","year":"2014","journal-title":"PharmacoEconomics"},{"key":"key2025101120015500_ref98-bib98","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3111\/13696998.2012.722572","article-title":"Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting","volume":"16","author":"Blohmer","year":"2013","journal-title":"J Med Econ"},{"key":"key2025101120015500_ref99-bib99","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s10549-012-1989-5","article-title":"Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer","volume":"133","author":"Lamond","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"key2025101120015500_ref100-bib100","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1093\/jnci\/djr484","article-title":"Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer","volume":"104","author":"Hall","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"key2025101120015500_ref101-bib101","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cct.2012.08.006","article-title":"The value of comparative effectiveness research: projected return on investment of the RxPONDER trial (SWOG S1007)","volume":"33","author":"Wong","year":"2012","journal-title":"Contemp Clin Trials"},{"key":"key2025101120015500_ref102-bib102","first-page":"455","article-title":"Cost-effectiveness of 21-gene assay in node-positive, early-stage breast cancer","volume":"17","author":"Vanderlaan","year":"2011","journal-title":"Am J Manag Care"},{"key":"key2025101120015500_ref104-bib104","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1524-4733.2010.00700.x","article-title":"Populating an economic model with health state utility values: moving toward better practice","volume":"13","author":"Ara","year":"2010","journal-title":"Value Health"},{"key":"key2025101120015500_ref105-bib105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta17440","article-title":"Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis","volume":"17","author":"Ward","year":"2013","journal-title":"Health Technol Assess"},{"key":"key2025101120015500_ref106-bib106","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","article-title":"The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial","volume":"6","author":"Sledge","year":"2020","journal-title":"JAMA Oncol"},{"key":"key2025101120015500_ref107-bib107","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s10549-012-2121-6","article-title":"Mortality, leukemic risk, and cardiovascular toxicity of adjuvant anthracycline and taxane chemotherapy in breast cancer: a meta-analysis","volume":"135","author":"Petrelli","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"key2025101120015500_ref108-bib108","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1200\/JCO.2013.54.6119","article-title":"Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience","volume":"33","author":"Wolff","year":"2015","journal-title":"J Clin Oncol"},{"key":"key2025101120015500_ref110-bib110","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10549-008-0300-2","article-title":"The impact of loco-regional recurrences on metastatic progression in early-stage breast cancer: a multistate model","volume":"117","author":"de Bock","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"key2025101120015500_ref111-bib111","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s11136-007-9202-8","article-title":"Health related quality of life in different states of breast cancer","volume":"16","author":"Lidgren","year":"2007","journal-title":"Qual Life Res"},{"key":"key2025101120015500_ref112-bib112","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1016\/j.ejca.2011.06.019","article-title":"The cost-effectiveness of adjuvant chemotherapy for early breast cancer: a comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses","volume":"47","author":"Campbell","year":"2011","journal-title":"Eur J Cancer"},{"key":"key2025101120015500_ref113-bib113","volume-title":"Estimating EQ-5D by Age and Sex for the UK","author":"Hern\u00e1ndez Alava","year":"2022"},{"key":"key2025101120015500_ref114-bib114","doi-asserted-by":"crossref","first-page":"e529","DOI":"10.1016\/j.clbc.2017.10.008","article-title":"Treatment patterns and outcomes of patients with metastatic ER+\/HER-2- breast cancer: a multicountry retrospective medical record review","volume":"18","author":"Kurosky","year":"2018","journal-title":"Clin Breast Cancer"},{"key":"key2025101120015500_ref115-bib115","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1586\/17474086.2016.1112735","article-title":"Economic burden associated with acute myeloid leukemia treatment","volume":"9","author":"Zeidan","year":"2016","journal-title":"Expert Rev Hematol"},{"key":"key2025101120015500_ref116-bib116","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/S0140-6736(09)60740-6","article-title":"Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial","volume":"373","author":"Ellis","year":"2009","journal-title":"Lancet"},{"key":"key2025101120015500_ref120-bib120","volume-title":"British National Formulary","author":"Joint Formulary Committee"},{"key":"key2025101120015500_ref121-bib121","volume-title":"Unit Costs of Health and Social Care 2020.","author":"Curtis","year":"2020"},{"key":"key2025101120015500_ref122-bib122","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1016\/S0960-9776(19)30350-9","article-title":"Ten-year clinical outcomes in >1000 node-negative (N0) Estrogen Receptor (ER)+ breast cancer (BC) patients (Pts) where treatment decisions incorporated the Recurrence Score Results: a registry analysis using TAILORx categorization","volume":"44","author":"Stemmer","year":"2019","journal-title":"Breast"},{"key":"key2025101120015500_ref124-bib124","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/sj.bjc.6603887","article-title":"Health care costs for the treatment of breast cancer recurrent events: estimates from a UK-based patient-level analysis","volume":"97","author":"Karnon","year":"2007","journal-title":"Br J Cancer"},{"key":"key2025101120015500_ref125-bib125","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J Clin Oncol"},{"key":"key2025101120015500_ref127-bib127","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer","volume":"379","author":"Sparano","year":"2018","journal-title":"N Engl J Med"},{"key":"key2025101120015500_ref130-bib130","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1200\/JCO.2016.70.3959","article-title":"Impact of 70-gene signature use on adjuvant chemotherapy decisions in patients with estrogen receptor-positive early breast cancer: results of a prospective cohort study","volume":"35","author":"Kuijer","year":"2017","journal-title":"J Clin Oncol"},{"key":"key2025101120015500_ref131-bib131","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s10549-020-05578-6","article-title":"The impact of Oncotype DX breast cancer assay results on clinical practice: a UK experience","volume":"180","author":"Crolley","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"key2025101120015500_ref132-bib132","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-019-6311-z","article-title":"The clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer","volume":"19","author":"Wang","year":"2019","journal-title":"BMC Cancer"},{"key":"key2025101120015500_ref133-bib133","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3310\/hta14Suppl1-10","article-title":"Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia","volume":"14","author":"Edlin","year":"2010","journal-title":"Health Technol Assess"},{"key":"key2025101120015500_ref134-bib134","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s10549-017-4340-3","article-title":"Patterns and predictors of first and subsequent recurrence in women with early breast cancer","volume":"165","author":"Geurts","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"key2025101120015500_ref135-bib135","doi-asserted-by":"crossref","first-page":"e288","DOI":"10.3747\/co.v18i6.810","article-title":"The cost-utility of adjuvant chemotherapy using docetaxel and cyclophosphamide compared with doxorubicin and cyclophosphamide in breast cancer","volume":"18","author":"Younis","year":"2011","journal-title":"Current Oncol"},{"key":"key2025101120015500_ref136-bib136","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/sj.bjc.6604911","article-title":"The total hospital and community UK costs of managing patients with relapsed breast cancer","volume":"100","author":"Thomas","year":"2009","journal-title":"Br J Cancer"},{"key":"key2025101120015500_ref137-bib137","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s41669-021-00278-3","article-title":"Cost effectiveness of gemtuzumab ozogamicin in the first-line treatment of acute myeloid leukaemia in the UK","volume":"5","author":"Russell-Smith","year":"2021","journal-title":"PharmacoEcon Open"},{"key":"key2025101120015500_ref138-bib138","doi-asserted-by":"crossref","first-page":"5664","DOI":"10.1200\/JCO.2006.07.3916","article-title":"Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial","volume":"24","author":"Roch\u00e9","year":"2006","journal-title":"J Clin Oncol"},{"key":"key2025101120015500_ref139-bib139","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.1200\/JCO.2015.61.9510","article-title":"Epirubicin plus cyclophosphamide followed by docetaxel versus epirubicin plus docetaxel followed by capecitabine as adjuvant therapy for node-positive early breast cancer: results from the GEICAM\/2003\u201310 study","volume":"33","author":"Mart\u00edn","year":"2015","journal-title":"J Clin Oncol"},{"key":"key2025101120015500_ref140-bib140","first-page":"3407","article-title":"Nab-paclitaxel monotherapy as a treatment of patients with metastatic breast cancer in routine clinical practice","volume":"33","author":"Aigner","year":"2013","journal-title":"Anticancer Res"},{"key":"key2025101120015500_ref141-bib141","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1200\/JCO.2008.18.4028","article-title":"Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735","volume":"27","author":"Jones","year":"2009","journal-title":"J Clin Oncol"},{"key":"key2025101120015500_ref142-bib142","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.3390\/cancers14133221","article-title":"The comparative safety of epirubicin and cyclophosphamide versus docetaxel and cyclophosphamide in lymph node-negative, HR-positive, HER2-negative breast cancer (ELEGANT): a randomized trial","volume":"14","author":"Liu","year":"2022","journal-title":"Cancers"},{"key":"key2025101120015500_ref144-bib144","volume-title":"Commercial Medicines Unit. Drugs and Pharmaceutical Electronic Market Information Tool (eMIT)","author":"Commercial Medicines Unit","year":"2021"},{"key":"key2025101120015500_ref146-bib146","volume-title":"Exploring the Cost of Care at the End of Life","author":"Georghiou","year":"2014"},{"key":"key2025101120015500_ref147-bib147","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1586\/erp.10.65","article-title":"Health-state utility values in breast cancer","volume":"10","author":"Peasgood","year":"2010","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"key2025101120015500_ref149-bib149","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1097\/00005650-200006000-00004","article-title":"One thousand health-related quality-of-life estimates","volume":"38","author":"Tengs","year":"2000","journal-title":"Med Care"},{"key":"key2025101120015500_ref150-bib150","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa1602253","article-title":"70-gene signature as an aid to treatment decisions in early-stage breast cancer","volume":"375","author":"Cardoso","year":"2016","journal-title":"N Engl J Med"},{"key":"key2025101120015500_ref151-bib151","volume-title":"Unit Costs of Health and Social Care 2021","author":"Jones","year":"2021"},{"key":"key2025101120015500_ref152-bib152","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"key2025101120015500_ref153-bib153","doi-asserted-by":"crossref","first-page":"A436","DOI":"10.1016\/j.jval.2017.08.216","article-title":"Cost effectiveness of ribociclib plus letrozole versus palbociclib plus letrozole for the treatment of post-menopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2\u2212) advanced or metastatic breast cancer from a us private third-party payer perspective","volume":"20","author":"Suri","year":"2017","journal-title":"Value Health"},{"key":"key2025101120015500_ref154-bib154","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1182\/blood.2021014401","article-title":"Cost-effectiveness of liposomal cytarabine\/daunorubicin in patients with newly diagnosed acute myeloid leukemia","volume":"139","author":"Bewersdorf","year":"2022","journal-title":"Blood"},{"key":"key2025101120015500_ref156-bib156","volume-title":"Drugs and Pharmaceutical Electronic Market Information Tool (eMIT)","author":"Commercial Medicines Unit","year":"2023"},{"key":"key2025101120015500_ref158-bib158","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","article-title":"20-year risks of breast cancer recurrence after stopping endocrine therapy at 5 years","volume":"377","author":"Pan","year":"2017","journal-title":"N Engl J Med"},{"key":"key2025101120015500_ref159-bib159","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall survival with ribociclib plus letrozole in advanced breast cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N Engl J Med"},{"key":"key2025101120015500_ref160-bib160","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s10549-020-05755-7","article-title":"Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+\/HER2\u2212 advanced breast cancer (PALOMA-1, TRIO-18)","volume":"183","author":"Finn","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"key2025101120015500_ref161-bib161","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1200\/JCO.2009.25.6693","article-title":"Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation","volume":"28","author":"Martin","year":"2010","journal-title":"J Clin Oncol"},{"key":"key2025101120015500_ref162-bib162","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1186\/s12955-020-01603-w","article-title":"Health-related quality of life and work productivity in UK patients with HER2-positive breast cancer: a cross-sectional study evaluating the relationships between disease and treatment stage","volume":"18","author":"Verrill","year":"2020","journal-title":"Health Qual Life Outcomes"},{"key":"key2025101120015500_ref163-bib163","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS18-P4-08-05","article-title":"Prediction of distant recurrence using EndoPredict among women with ER-positive, HER2-negative breast cancer with a maximum follow-up of 16 years","volume":"79","author":"Filipits","year":"2019","journal-title":"Cancer Res"},{"key":"key2025101120015500_ref165-bib165","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198529446.001.0001","volume-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"2005"},{"key":"key2025101120015500_ref166-bib166","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1524-4733.2003.00234.x","article-title":"Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR task force on good research practices \u2013 modeling studies","volume":"6","author":"Weinstein","year":"2003","journal-title":"Value Health"},{"key":"key2025101120015500_ref167-bib167","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2048926","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/sites\/journalslibrary\/files\/journal_data\/KGFD4040\/KGFD4040.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2048926","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T14:38:20Z","timestamp":1760193500000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/KGFD4040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":143,"alternative-id":["10.3310\/KGFD4040"],"URL":"https:\/\/doi.org\/10.3310\/kgfd4040","relation":{},"ISSN":["2046-4924"],"issn-type":[{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"},{"value":"03-2023","name":"contractual_start_date","label":"contractual_start_date","group":{"name":"article_history","label":"Article History"}},{"value":"10-2023","name":"editorial_review_begun","label":"editorial review begun","group":{"name":"article_history","label":"Article History"}},{"value":"02-2025","name":"accepted_for_publication","label":"Accepted for publication","group":{"name":"article_history","label":"Article History"}}]}}